China-based Sihuan Pharmaceutical Holdings Group Ltd’s subsidiary, Beijing Centergate Technologies (Holding) Co., Ltd (SHE: 000931), has announced that Sihuan Pharma is set to acquire an additional 9.56% stake in Heilongjiang Duoduo Pharmaceutical Co., Ltd. Upon the deal’s closure, Sihuan will own a 78.82% stake in Duoduo Pharma, maintaining its position as the controlling shareholder.
Duoduo Pharma: Company Profile and Capabilities
Duoduo Pharma is known for its robust production capabilities, including β-Lactam solid preparation, liquid preparation, external preparation, API, and Chinese medicine extraction workshops. The company is capable of producing 410 million injections and 4 billion solid preparations (tablets) annually. Duoduo Pharma’s 10 drug formulations and 142 varieties are all compliant with China’s GMP standards. The firm’s top market performers include tramadol, lacidophilin, and radix et rhizoma seu caulis acanthopanacis senticosi.
Future Outlook
The acquisition underscores Sihuan Pharmaceutical Holdings’ strategy to expand its presence in the Chinese pharmaceutical market. By increasing its stake in Duoduo Pharma, Sihuan aims to leverage the target company’s production capabilities and market presence to further enhance its portfolio of pharmaceutical products.-Fineline Info & Tech
